Thrombophilia

This study looks at how well a medicine called Ceprotin (TAK-662) works and how safe it is for people with congenital protein C deficiency, a rare inherited condition that raises the risk of dangerous blood clots. Participants receive the medicine through an IV as part of their u…

This early study tests a new drug called BAY 3389934 in 36 hospital ICU patients with sepsis-induced coagulopathy, a condition where the body forms dangerous blood clots. The main goal is to check safety and find the right dose. Researchers will monitor side effects and blood clo…

This pilot study tests efgartigimod, a drug that lowers harmful antibodies, in 15 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. Participants receive weekly infusions for 8 weeks, then are monitored for another …

This study tests a drug called Atenativ in people with a rare inherited condition that raises their risk of dangerous blood clots. The goal is to see if Atenativ can prevent clots during surgery or childbirth. About 38 adults and some teens will take part. The drug is given as an…

This study tests a drug called Atenativ, made from human plasma, in 120 adults who are resistant to heparin during planned heart surgery. Heparin is a blood thinner used to prevent clots during surgery, but some patients don't respond well. The drug aims to restore heparin's effe…

This study is collecting information from 40 patients with a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have been treated with daratumumab. The goal is to see how well daratumumab works and how safe it is for patients whose disease d…

This study tests whether the blood thinner apixaban can dissolve blood clots in the portal vein that develop more than a year after laparoscopic spleen surgery in people with cirrhosis. Twenty participants will take apixaban twice daily, and doctors will use ultrasound or CT scan…

This study looks at whether the blood thinner apixaban can safely dissolve blood clots in the portal vein (the main vein to the liver) that appear more than a year after spleen removal surgery. It involves 20 adults with cirrhosis who had their spleen removed. The goal is to see …

This early-stage study tests a single injection of CITY-FXI, a drug designed to lower clotting risk by targeting a protein called Factor XI. It includes healthy adults and those with Factor V Leiden or prothrombin G20210A mutations, which increase clot risk. The main goal is to c…

This study tests whether a simpler treatment for immune thrombotic thrombocytopenic purpura (iTTP) works as well as the standard approach. Instead of daily plasma exchange (an invasive procedure), patients receive plasma infusions, immune-suppressing drugs, and caplacizumab. The …

This study monitors 40 people in Japan with congenital thrombotic thrombocytopenic purpura (cTTP) who are receiving ADZYNMA (recombinant ADAMTS13) as part of their routine care. Researchers will track side effects and check if the drug improves platelet counts and ADAMTS13 activi…

This trial tests whether taking a low-dose aspirin pill every day for six weeks after delivery can prevent dangerous blood clots in the legs or lungs as effectively as the standard daily heparin injections. The study enrolls people who have given birth and have one or more risk f…

This study is collecting long-term safety and effectiveness data on treatments for various blood disorders, including hemophilia, sickle cell disease, and clotting disorders. It aims to enroll 3000 people of any age with these conditions. Researchers will monitor side effects, co…

This study is creating a risk assessment system to predict blood clotting abnormalities in women with polycystic ovary syndrome (PCOS). Researchers will analyze hormone, metabolic, and genetic factors in 100 participants aged 14 to 45. The goal is to help doctors personalize care…

This study looks at the real-world safety of Adzynma, a lab-made protein, in people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder. Researchers will review medical records of about 50 children and adults to see how many develop allergi…

This study enrolls 100 adults who have or may have Factor V Leiden or Prothrombin G20210A mutations, which increase the risk of blood clots. Participants undergo genetic testing to confirm their status, then attend a site visit for basic health checks like blood pressure, ECG, an…

This study looks at blood samples from 44 people with thrombotic thrombocytopenic purpura (TTP) to understand how certain immune cells (B and T lymphocytes) react to the ADAMTS13 protein during different stages of the disease. The goal is to find early warning signs that could pr…

This study looks at cancer patients who have a type of blood clot called superficial venous thrombosis (SVT). About 15-20% of SVTs happen in people with cancer, but there are no clear treatment guidelines for them. Researchers will observe 1,576 patients to see how different bloo…

This study is testing whether patients recovering from hip or knee replacement can safely skip elastic compression stockings and rely only on blood-thinning drugs to prevent dangerous blood clots. Over 1,200 participants will be randomly assigned to receive either drugs plus stoc…

This study looks at whether a specific gene, TNFAIP3, is linked to immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare blood clotting disorder. Researchers will compare genetic data from 400 people with iTTP and healthy volunteers to see if gene variations affect d…

This study looks at two types of blood thinners—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—to see which works better at preventing repeat blood clots in people with a low-risk form of antiphospholipid syndrome (APS). APS is an autoimmune condition that ra…

This study looks back at how antithrombin, a blood-clotting protein, was prescribed to 160 intensive care patients at Strasbourg University Hospitals over two years. Researchers want to see if these prescriptions were appropriate and how the drug was used in real-world settings. …

This study reviews medical records from over 1,200 people with immune thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. The goal is to understand long-term health problems, such as heart disease and thinking issues, that survivors face. By an…

This study looks at why cancer patients have a much higher risk of developing blood clots. Researchers will collect blood clots from 120 patients (with and without cancer) who undergo a procedure to remove clots. They will analyze the clots for cancer cells and other factors to b…